Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Interim Results

16 Oct 2008 07:00

RNS Number : 9607F
Oxeco PLC
16 October 2008
ย 

๏ปฟ

16 October 2008

Oxeco Plc (the "Company"ย or theย "Group" )

Interim financial report for the six months ended 31 July 2008

Chairman's Statement

I am pleased toย report on yourย Group'sย performanceย for the six months ended 31 July 2008.ย 

Oxecoย Plcย is a holding and management company, specialising in the development and growth of tradingย businessesย within theย technology and science sectors. The Company currently hasย one subsidiary, Oxray Ltd, which was acquired in June 2007 and is aย start up business which aims to become a leading provider of molecular structure determination services to both industry and academic institutions.ย 

Theย unauditedย consolidated loss before tax for the Groupย inย six months to 31 July 2008ย amounted toย ยฃ105,000 compared to ยฃ3,000 for the comparable period from incorporation on 17 October 2006 to 31 July 2007. Consolidated net assets at 31 July 2008 amounted to ยฃ4.77 million including cash balances of ยฃ2.64 million versus net assetsย of ยฃ4.93 millionย and cashย balances of ยฃ2.81 million a year earlier at 31 July 2007.ย The cash outflow for the Group during theย six months to 31 July 2008 amounted to ยฃ120,000 and cash balances continue to be managed prudently, with tight cost control.

Oxray's primary objectives are the development of novel X-ray crystallography structure determination software and the provision of a small-molecule X-ray crystallography structure service. The service usesย a web portal behind which the company canย work toย maximiseย the extent to which the service can be automated. Theย Companyย offersย standardisedย response times to its customers but alsoย offersย market premium services such as a fast-response and extended scientific reporting suitable to support customers' patent applications.ย Oxray expects to complete the initial development of it's X-ray crystallography structure determinationย softwareย within the next six monthsย and will then focus on the marketing of the service and the establishment of a solid customer base.

Oxecoย Plcย is well capitalised andย I am confident that your Company will continue toย make considerable progress in its development duringย the second half of the yearย despite turbulent financial markets.ย Your Directorsย are continuing to evaluate a range of new commercial and acquisition opportunities which they believe fulfil the Company's original objectives of investing in the technology and science sectors, and especially those which are complimentary to the existing Group activities.

Finally I would like to conclude by thanking our employees and management for their hard work and support in the growth and development of theย Groupย in the period.

Jussi Westergren

Executive Chairman

Contact:

Michael Bretherton

Oxeco plc

www.oxecoplc.com

+44 (0) 207352 8989

ย Ray Zimmerman/Jonathan Evans

Zimmerman Adams International Limited

+44 (0) 207 060 1760

Daniel Briggs

Religare Hichens, Harrison plc

+44 (0) 207 382 7776

ย 

ย 

ย 

ย 

OXECO PLC

CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 31 JULY 2008

ย 
Notes
Six months to 31 July
2008
(Unaudited)
Period to
31 July
2007
(Unaudited)
Period to
31 January
2008
(Audited)
ย 
ย 
ยฃ000
ยฃ000
ยฃ000
ย 
ย 
ย 
ย 
ย 
Revenue
ย 
6
-
7
Administrative expenses
ย 
(188)
(95)
(243)
ย 
ย 
ย 
ย 
ย 
Operating Loss
ย 
(182)
(95)
(236)
ย 
ย 
ย 
ย 
ย 
Interest receivable
ย 
77
92
178
ย 
ย 
ย 
ย 
ย 
Loss before tax
ย 
(105)
(3)
(58)
ย 
ย 
ย 
ย 
ย 
Taxation
2
3
โ€“
(5)
ย 
ย 
ย 
ย 
ย 
Loss for the period
ย 
(102)
(3)
(63)
Earnings per share Basic and Diluted
3
(0.02p)
(0.00)p
(0.01)p
ย 
ย 

ย 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

The loss for the period arises from the Group's continuing operations.

CONDENSED CONSOLIDATEDย STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS TO 31 JULY 2008

ย 
Share Capital ยฃ000
Share Premium ยฃ000
Retained Loss ยฃ000
Total Equity ยฃ000
At 17 October 2006
โ€“
โ€“
โ€“
โ€“
Issue of shares
600
4,500
โ€“
5,100
Expenses of issue of shares
โ€“
(167)
โ€“
(167)
Loss for the period
โ€“
โ€“
(3)
(3)
At 31 July 2007
600
4,333
(3)
4,930
Loss for the period
-
-
(60)
(60)
At 31 January 2008
600
4,333
(63)
4,870
Loss for the period
-
-
(102)
(102)
At 31 July 2008
600
4,333
(165)
4,768
ย 
ย 

OXECO PLC

CONDENSED CONSOLIDATED BALANCE SHEET

AS AT 31 JULY 2008

ย 
Notes
31 July 2008
31 July 2007
31 January 2008
ย 
ย 
(Unaudited)
(Unaudited)
(Audited)
ย 
ย 
ยฃ000
ยฃ000
ยฃ000
ASSETS
Non-current assets
ย 
ย 
ย 
ย 
Property, plant and equipment
ย 
1
1
2
Intangible assets - goodwill
ย 
2,120
2,120
2,120
Total non-current assets
ย 
2,121
2,121
2,122
ย 
ย 
ย 
ย 
ย 
Current assets
ย 
ย 
ย 
ย 
Trade and other receivables
ย 
38
16
29
Cash and cash equivalents
ย 
2,641
2,816
2,761
Total current assets
ย 
2,679
2,832
2,790
ย 
ย 
ย 
ย 
ย 
TOTAL ASSETS
ย 
4,800
4,953
4,912
ย 
ย 
ย 
ย 
ย 
LIABILITIES
ย 
ย 
ย 
ย 
Current Liabilities
ย 
ย 
ย 
ย 
Trade and other payables
ย 
(30)
(23)
(37)
Current taxation
ย 
(2)
-
(5)
ย 
ย 
ย 
ย 
ย 
TOTAL LIABILITIES
ย 
(32)
(23)
(42)
ย 
ย 
ย 
ย 
ย 
NET ASSETS
ย 
4,768
4,930
4,870
ย 
ย 
ย 
ย 
ย 
EQUITY
ย 
ย 
ย 
ย 
Issued capital
3
600
600
600
Share premium
ย 
4,333
4,333
4,333
Revenue reserve
ย 
(165)
(3)
(63)
TOTAL EQUITY SHAREHOLDERSโ€™ FUNDS
ย 
4,768
4,930
4,870
ย 
ย 

ย 

Approved by the Board andย authorisedย for issueย onย 16ย October 2008.

J P Westergren Mย A Bretherton

Chairman Finance Director

OXECO PLC

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTHS ENDEDย 31 JULY 2008

ย 
Six months to
31 July 2008
Period to
31 July 2007
Period to
31 January 2008
ย 
(Unaudited)
(Unaudited)
(Audited)
ย 
ยฃ000
ยฃ000
ยฃ000
OPERATING ACTIVITIES
ย 
ย 
ย 
Operating loss before taxation
(182)
(95)
(236)
Depreciation of property, plant and equipment
1
-
-
Increase in trade and other receivables
(9)
(16)
(29)
Decrease in trade and other payables
(7)
(30)
(15)
Net cash outflow from operations
(197)
(141)
(280)
ย 
ย 
ย 
ย 
INVESTING ACTIVITIES
ย 
ย 
ย 
Purchase of property, plant and equipment
-
-
(2)
Acquisition of subsidiaries
-
(100)
(100)
Cash and bank in subsidiaries at acquisition
-
32
32
Net cash outflow from investing activities
-
(68)
(70)
ย 
ย 
ย 
ย 
FINANCING ACTIVITIES
ย 
ย 
ย 
Proceeds from issue of share capital
-
3,100
3,100
Expenses of issue of share capital
-
(167)
(167)
Interest received
77
92
178
Net cash inflow from financing activities
77
3,025
3,111
ย 
ย 
ย 
ย 
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
(120)
2,816
2,761
ย 
ย 
ย 
ย 
Cash and cash equivalents at start of period
2,761
โ€“
-
ย 
ย 
ย 
ย 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
2,641
2,816
2,761
ย 
ย 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

OXECO PLC

NOTES TO THE CONDENSED FINANCIAL STATEMENTSย 

FOR THE SIX MONTHS ENDEDย 31 JULY 2008

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The interim financial statements of Oxeco Plc are unaudited condensed consolidated financial statements for the period for the six months period to 31 July 2008. These includeย unaudited comparatives for theย period from incorporation onย 17ย Octoberย 2006ย to 31 July 2007 together with audited comparatives for the period fromย incorporation on 17 October 2006 to 31 July 2007.

The condensed consolidated financial statements have been prepared under the historic cost convention and incorporate the financials of Oxeco Plc for the period and its subsidiary undertaking from the date of acquisition.

The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the period ended 31 January 2008.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the period to 31 January 2008 have been reported on by the Company's auditors and have been filed with the Registrar of Companies. The report of the auditors was unqualifiedย and did not contain a statement under section 237(2) or 237(3) of the Companies Act 1985.

2) TAXATION

The accrued tax charge for the six month period is based on an estimated effective tax rate of nil, after allowance for utilisation of tax losses brought forward in subsidiaries and prior year adjustments, (period to 31 July 2007: effective tax rate nil, period to 31 January 2008: effective tax rate 8.6 per cent.).

3) LOSS PER SHARE

Basic loss per share is based on the net loss for theย period of ยฃ102,000ย attributable to equity holders of the parent divided by the weighted average number of ordinary shares in issue during the period ofย 600,000,000, (period to 31 July 2007: loss ยฃ3,000 divided by the weighted average number of 353,658,537ย shares; period to 31 January 2008: loss ยฃ63,000 divided by the weighted average of 456,050,955 shares). Fully diluted earnings per share are the same as basic earnings per share.

4) SHARE CAPITAL
Number
ยฃโ€™000
Authorised ordinary shares of 1p:
ย 
ย 
ย 
ย 
ย 
Atย 31 July 2007,ย 31 January 2008 and 31 July 2008
1,000,000,000
1,000
ย 
ย 
ย 
Allotted, issued and fully paid ordinary shares of 1p:
ย 
ย 
ย 
ย 
ย 
Atย 31 July 2007,ย 31 January 2008 and 31 July 2008
600,000,000
600
ย 
ย 

5) RELATED PARTY TRANSACTIONS

During the periodย the Companyย entered into the following transactions with Ora Capital Partners Plcย (ORA)ย which as at 31 July 2008ย heldย 45.25% of theย Company'sย issued share capital.

ย 
Six months to
31 July
ย 2008
Period to
31 July
2007
Period to
31 January 2008
ย 
(Unaudited)
(Unaudited)
(Audited)
ย 
ยฃ000
ยฃ000
ยฃ000
Management consultancy fees charged by ORA
6
7
18
ย 

ย 

During the period the Company's wholly owned subsidiary, Oxray Ltd, borrowed ยฃnil (31 July 2007: ยฃ100,000)ย ย from the Company for working capital purposes. The loan is non-interest bearing, is repayable on demand and the outstanding balance at 31 July 2008 was ยฃ200,000 (31 July 2007: ยฃ100,000).

6)ย INTERIM FINANCIAL REPORT

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.oxecoplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
IR ILFLDISLELIT
Date   Source Headline
30th Mar 20207:00 amRNSUpdate in relation to working capital position
20th Mar 20207:00 amRNSDirectorate Change
6th Feb 20207:15 amEQSHardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
4th Feb 202011:47 amRNSResolution of Cyber Security Incident
28th Jan 202010:02 amRNSNotice of cyber security incident
22nd Jan 20207:00 amRNSTrading Update
14th Jan 20204:40 pmRNSSecond Price Monitoring Extn
14th Jan 20204:35 pmRNSPrice Monitoring Extension
21st Nov 20194:35 pmRNSPrice Monitoring Extension
18th Nov 20194:03 pmRNSDirectorate Change
14th Nov 20194:00 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSUpdated loan facility agreement with MidCap
13th Nov 20193:35 pmRNSHolding(s) in Company
13th Nov 20193:17 pmRNSHolding(s) in Company
11th Nov 20192:05 pmRNSSecond Price Monitoring Extn
11th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSUpdate in relation to loan facility
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.